At least three CETP inhibitors have failed in clinical trials to conclude a protective effect against coronary heart disease (CHD), but the successful trial of Anacetrapib showed a modest benefit when used with statins (Bowman et al., 2017). This evidence concerns the gene CETP and coronary artery disorder.